---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-000905"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:49:32.345761+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting

## Summary
- Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.
- Separation pay of $565,000 (12 months) plus $115,724 prorated 2025 target bonus; retains $100K signing bonus.
- All unvested stock options and RSUs forfeited (no vesting before one-year anniversary).
- Company expects to enter a consulting arrangement with Zuraw for Q1 2026 to assist transition.
- Separation includes 12-month non-compete, non-disparagement, and standard confidentiality covenants.

## SEC filing metadata
- accession: 0001193125-26-000905
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312526000905/0001193125-26-000905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312526000905/vor-20251231.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-000905
- JSON: https://secwatch.observer/filing/0001193125-26-000905.json
- Plain text: https://secwatch.observer/filing/0001193125-26-000905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.